EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Intellia Therapeutics EBITDA Margin % Related Terms
Intellia Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Intellia Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTLA vs AUPH, OCUL, VRDN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Intellia Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a EBITDA Margin % of -653.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Intellia Therapeutics and its competitors. According to the industry distribution chart, Intellia Therapeutics ranks #698 out of 945 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Intellia Therapeutics' EBITDA Margin % too high?
Intellia Therapeutics' current EBITDA Margin % is -653.44%. Based on the distribution chart, Intellia Therapeutics ranks #698 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' EBITDA Margin % compare to AUPH and OCUL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #698 out of 945 companies for EBITDA Margin %. This places Intellia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current EBITDA Margin % is -653.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.67, compared to a current price of $15.43 — trading 25.4% below its estimated fair value. The current EBITDA Margin % is -653.44%. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current EBITDA Margin % is -653.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $15.43 is trading 25.4% below its estimated GF Value™ of $20.67.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
EBITDA Margin %: -653.44%
GF Value™: $20.67 vs. price of $15.43 (25.4% below fair value)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
